Abstract: An in vitro culture medium for embryos consisting of IVF culture medium additionally containing G-CSF at a concentration of at least 0.5 ng/ml, preferably between 1.0 and 5.0 ng/ml, is described; a method for in vitro embryo culture, comprising the steps of incubating a plurality of embryos in an in vitro culture medium consisting of IVF culture medium additionally containing G-CSF at a concentration of at least 0.5 ng/ml and growing such embryos until the 8-cell stage is reached is also described.

Abstract: The invention relates to GM-CSF for use in a method for the prevention of spontaneous abortion in a subject suffering from recurrent miscarriage, comprising administering to said subject an effective amount of GM-CSF as sole active substance, wherein said method also prevents or reduces the likelihood of embryo implantation failure in the subject undergoing an assisted reproduction procedure.

Abstract: The use of degarelix in the treatment of endometriosis, in particular in the treatment of endometriotic ovarian cysts and recurrent endometriotic lesions following surgery and in the treatment of endometriosis and/or endometriotic ovarian cysts in patients who plan to undergo assisted reproduction, is described, wherein this treatment is performed before the patients are subjected to assisted reproduction; degarelix is administered for this purpose as a single dose of 80-120 mg, preferably 80 mg, subcutaneously.

Abstract: The invention relates to GM-CSF for use in a method for the prevention of spontaneous abortion in a subject suffering from recurrent miscarriage, comprising administering to said subject an effective amount of GM-CSF as sole active substance, wherein said method also prevents or reduces the likelihood of embryo implantation failure in the subject undergoing an assisted reproduction procedure.

Abstract: The use of degarelix in the treatment of endometriosis, in particular in the treatment of endometriotic ovarian cysts and recurrent endometriotic lesions following surgery and in the treatment of endometriosis and/or endometriotic ovarian cysts in patients who plan to undergo assisted reproduction, is described, wherein this treatment is performed before the patients are subjected to assisted reproduction; degarelix is administered for this purpose as a single dose of 80-120 mg, preferably 80 mg, subcutaneously.

Abstract: An in vitro culture medium for embryos consisting of IVF culture medium additionally containing G-CSF at a concentration of at least 0.5 ng/ml, preferably between 1.0 and 5.0 ng/ml, is described; a method for in vitro embryo culture, comprising the steps of incubating a plurality of embryos in an in vitro culture medium consisting of IVF culture medium additionally containing G-CSF at a concentration of at least 0.5 ng/ml and growing such embryos until the 8-cell stage is reached is also described.